Multiple System Atrophy Clinical Trials 2023

What are the top hospitals conducting multiple system atrophy research?

When it comes to advancing research and treatment options for multiple system atrophy (MSA), several leading hospitals are making significant strides. Vanderbilt University Medical Center in Nashville takes the forefront with its dedication to combating this rare neurological disorder. With seven ongoing MSA trials and a total of 12 completed studies, Vanderbilt has been actively involved in researching MSA since their first recorded trial in 2008. Notably, within the same medical center lies the Autonomic Dysfunction Center, which focuses specifically on MSA-related autonomic dysfunction. This specialized center is currently conducting six active clinical trials for MSA and has contributed five previous investigations since initiating their first trial in 2016.

Meanwhile, the renowned Mayo Clinic located in Rochester also plays a vital role in advancing our understanding of MSA. With four active clinical trials underway and a commendable history of 11 prior studies dedicated to this condition, Mayo Clinic began its pioneering investigation into MSA back in 2011.

In Farmington Hills, Michigan, Quest Research Institute contributes significantly to finding new treatment options for individuals living with MSA. Despite being relatively recent entrants into the field with their first recorded trial occurring only in 2019, they have already established three ongoing clinical trials and have conducted an additional four experiments pertaining to multiple system atrophy.

Lastly but not least importantly ,the University of Texas Southwestern Medical Center situated proudly Dallas joins these esteemed institutions as they also prioritize investigating solutions for people affected by this complex condition.There are three prevailing active tests while having carried out comparable four explorations previously tracing back only ten years ago starting from2011

These noteworthy hospitals demonstrate unwavering commitment towards bettering outcomes for those impacted by multiple system atrophy through extensive research efforts. Each study brings us closer to unlocking answers that may lead to improved treatments or possibly even a cure someday soon

Which are the best cities for multiple system atrophy clinical trials?

In the realm of multiple system atrophy clinical trials, several cities emerge as key players in advancing research and treatment options. With 14 active trials, Nashville, Tennessee stands out for investigating ATH434, abdominal compression, accelerometer usage, and more. New york City follows closely behind with 8 ongoing studies exploring interventions such as Zoledronic acid (ZA), Lu AF82422, delayed start-PD protocols, among others. Additionally, Chicago and Boston each boast 6 active trials focusing on treatments like Zoledronic acid (ZA), ATH434 Arm 1, Lu AF82422 along with other potential breakthroughs. Lastly, Farmington Hills in Michigan contributes to the field with 5 active trials studying TAK-341 Dose 2 variants alongside interventions like AAV2-GDNF gene therapy. These cities represent hubs of research excellence where individuals affected by multiple system atrophy can access cutting-edge clinical trials offering hope for improved outcomes and quality of life.

Which are the top treatments for multiple system atrophy being explored in clinical trials?

Clinical trials for multiple system atrophy are exploring several top treatments. ATH434, a promising drug, is currently being tested in two active trials specifically targeting this condition. Another innovative approach involves the use of abdominal compression, which has also shown potential in two ongoing trials dedicated to multiple system atrophy. Additionally, an accelerometer-based intervention is gaining traction with one active trial focusing on this progressive disorder. These research endeavors, initiated between 2015 and 2023, hold promise for advancing our understanding and treatment options for multiple system atrophy patients.

What are the most recent clinical trials for multiple system atrophy?

The field of multiple system atrophy (MSA) is advancing with promising clinical trials that offer hope for those affected by this debilitating condition. Among the most recent trials is ONO-2808, a Phase 2 study aimed at evaluating its effectiveness in treating MSA. Additionally, there is an ongoing Long-Term Extension Period trial in Phase 3, which seeks to further understand and assess potential treatments for MSA patients. Another notable study focuses on Delayed Start - PD as a possible intervention for MSA. ATH434 is also being investigated in a Phase 2 trial to determine its efficacy against this disease. Lastly, exciting advancements are being made through AAV2-GDNF gene therapy research in a Phase 1 trial. These clinical trials demonstrate the dedication of researchers towards finding better therapies and improving the quality of life for individuals living with MSA.

What multiple system atrophy clinical trials were recently completed?

Recently completed clinical trials have made significant strides in the realm of multiple system atrophy, a rare neurodegenerative disorder. In December 2020, Brigham and Women's Hospital concluded their trial on [F-18]PBR06 to evaluate its potential as a diagnostic tool or treatment option for this challenging condition. Another noteworthy trial led by Biohaven Pharmaceuticals reached completion in July 2019, investigating the effectiveness of Verdiperstat for multiple system atrophy. These studies mark important advancements in our understanding and management of this complex disease, offering hope to those affected by it.